1209 related articles for article (PubMed ID: 27368880)
1. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
[TBL] [Abstract][Full Text] [Related]
2. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
[TBL] [Abstract][Full Text] [Related]
3. The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer.
Karaoglu I; van der Heijden AG; Witjes JA
World J Urol; 2014 Jun; 32(3):651-9. PubMed ID: 24166285
[TBL] [Abstract][Full Text] [Related]
4. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
Pichler R; Tulchiner G; Fritz J; Schaefer G; Horninger W; Heidegger I
Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318
[No Abstract] [Full Text] [Related]
5. [Urine cytology and urine markers. Significance for clinical practice].
Tritschler S; Zaak D; Knuechel R; Stief CG
Urologe A; 2006 Nov; 45(11):W1441-7; quiz W1448. PubMed ID: 17063350
[TBL] [Abstract][Full Text] [Related]
6. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
7. Clinical Decision Making in Surveillance of Non-Muscle-Invasive Bladder Cancer: The Evolving Roles of Urinary Cytology and Molecular Markers.
Zuiverloon TCM; de Jong FC; Theodorescu D
Oncology (Williston Park); 2017 Dec; 31(12):855-62. PubMed ID: 29297169
[TBL] [Abstract][Full Text] [Related]
8. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.
Witjes JA; Morote J; Cornel EB; Gakis G; van Valenberg FJP; Lozano F; Sternberg IA; Willemsen E; Hegemann ML; Paitan Y; Leibovitch I
Eur Urol Oncol; 2018 Sep; 1(4):307-313. PubMed ID: 31100252
[TBL] [Abstract][Full Text] [Related]
9. [Aftercare of non-muscle invasive bladder cancer].
Schulz GB; Schlenker B; Stief CG
Urologe A; 2019 Aug; 58(8):943-952. PubMed ID: 31175377
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.
Blick CG; Nazir SA; Mallett S; Turney BW; Onwu NN; Roberts IS; Crew JP; Cowan NC
BJU Int; 2012 Jul; 110(1):84-94. PubMed ID: 22122739
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert
Cowan B; Klein E; Jansz K; Westenfelder K; Bradford T; Peterson C; Scherr D; Karsh LI; Egerdie B; Witjes A; Trainer A; Harris R; Goldfarb B; Flax S; Kroeger R; Boyd B; Liao J; Patel S; Bridge J; Reuter V; Quigley N; Brown S; Zhao S; Satya M; Bates M; Simon IM; Campbell S; Lotan Y
BJU Int; 2021 Dec; 128(6):713-721. PubMed ID: 33793062
[TBL] [Abstract][Full Text] [Related]
12. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
13. Urine Cytology Rarely Escalates Clinical Management in the Surveillance of Non-muscle-Invasive Bladder Cancer.
Feiertag N; Barry E; Abramson M; Park JY; Kovac E; Aboumohamed A; Watts K; Sankin A
Clin Genitourin Cancer; 2023 Apr; 21(2):258-264. PubMed ID: 36621462
[TBL] [Abstract][Full Text] [Related]
14. Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer.
Raitanen MP; Leppilahti M; Tuhkanen K; Forssel T; Nylund P; Tammela T;
Ann Chir Gynaecol; 2001; 90(4):261-5. PubMed ID: 11820414
[TBL] [Abstract][Full Text] [Related]
15. Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature.
Soukup V; Babjuk M; Bellmunt J; Dalbagni G; Giannarini G; Hakenberg OW; Herr H; Lechevallier E; Ribal MJ
Eur Urol; 2012 Aug; 62(2):290-302. PubMed ID: 22609313
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer.
Trenti E; D'Elia C; Mian C; Schwienbacher C; Hanspeter E; Pycha A; Kafka M; Degener S; Danuser H; Roth S; Pycha A
Cancer Cytopathol; 2019 Jul; 127(7):465-469. PubMed ID: 31154670
[TBL] [Abstract][Full Text] [Related]
17. FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.
Beukers W; van der Keur KA; Kandimalla R; Vergouwe Y; Steyerberg EW; Boormans JL; Jensen JB; Lorente JA; Real FX; Segersten U; Orntoft TF; Malats N; Malmström PU; Dyrskjot L; Zwarthoff EC
J Urol; 2017 Jun; 197(6):1410-1418. PubMed ID: 28049011
[TBL] [Abstract][Full Text] [Related]
18. Human complement factor H related protein test for monitoring bladder cancer.
Raitanen MP; Marttila T; Nurmi M; Ala-Opas M; Nieminen P; Aine R; Tammela TL;
J Urol; 2001 Feb; 165(2):374-7. PubMed ID: 11176376
[TBL] [Abstract][Full Text] [Related]
19. Stepwise application of urine markers to detect tumor recurrence in patients undergoing surveillance for non-muscle-invasive bladder cancer.
Todenhöfer T; Hennenlotter J; Esser M; Mohrhardt S; Aufderklamm S; Böttge J; Rausch S; Mischinger J; Bier S; Gakis G; Kuehs U; Stenzl A; Schwentner C
Dis Markers; 2014; 2014():973406. PubMed ID: 25587206
[TBL] [Abstract][Full Text] [Related]
20. Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer.
Todenhöfer T; Hennenlotter J; Guttenberg P; Mohrhardt S; Kuehs U; Esser M; Aufderklamm S; Bier S; Harland N; Rausch S; Gakis G; Stenzl A; Schwentner C
BMC Cancer; 2015 Mar; 15():155. PubMed ID: 25884545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
